论文部分内容阅读
目的:研究地西他滨联合CAG方案对急性髓系白血病患者血清γ干扰素(IFN-γ)、α-羟丁酸脱氢酶(HBDH)与乳酸脱氢酶(LDH)水平的影响。方法:选取2013年2月至2016年10月我院接诊的70例急性髓系白血病患者作为本次研究对象,并按照随机数表法分为观察组(35例)和对照组(35例)。两组患者均采用常规治疗,对照组在基础治疗上,加用CAG方案,静脉注射阿克拉霉素,每次20 mg;粒细胞集落刺激因子,每次300μg;皮下注射阿糖胞苷,每次10~15 mg/m2;观察组在对照组基础上,加用15mg/m2地西他滨静脉滴注治疗。观察和比较两组患者的临床疗效,治疗前后血清IFN-γ、HBDH、LDH水平的变化及不良反应的发生情况。结果:治疗后,观察组总有效率显著高于对照组[91.42%(32/35)vs.68.57%(24/35)](P<0.05);血清IFN-γ、HBDH、LDH水平显著低于对照组[(3.21±1.01)pg/mL vs.(5.13±1.90)pg/mL,(103.62±26.39)U/L vs.(118.80±28.60)U/L,(101.36±27.32)U/L vs.(123.08±30.59)U/L](P<0.05);不良反应总发生率显著亦明显低于对照组[20.00%(7/35)vs.42.85%(15/35)](P<0.05)。结论:地西他滨联合CAG方案治疗急性髓系白血病患者的临床疗效优于单用CAG方案,可能与其显著降低患者血清IFN-γ、HBDH与LDH的水平有关。
Objective: To investigate the effects of decitabine combined with CAG on serum levels of IFN-γ, α-hydroxybutyrate dehydrogenase (HBDH) and lactate dehydrogenase (LDH) in patients with acute myeloid leukemia. Methods: Seventy patients with acute myeloid leukemia admitted to our hospital from February 2013 to October 2016 were selected as the study subjects and divided into observation group (35 cases) and control group (35 cases ). The two groups of patients were treated with conventional treatment, the control group in the basic treatment, plus CAG program, intravenous aclacinomycin, each 20 mg; granulocyte colony stimulating factor, each 300μg; subcutaneous injection of cytarabine, each Times 10 ~ 15 mg / m2; observation group on the basis of the control group, plus 15mg / m2 intravenous infusion of decitabine treatment. To observe and compare the clinical efficacy of two groups of patients before and after treatment, serum levels of IFN-γ, HBDH, LDH levels and adverse reactions. Results: After treatment, the total effective rate in the observation group was significantly higher than that in the control group [91.42% (32/35) vs 68.57% (24/35)] (P <0.05), and the levels of serum IFN-γ, HBDH and LDH were significantly lower In the control group [(3.21 ± 1.01) pg / mL vs. (5.13 ± 1.90) pg / mL, (103.62 ± 26.39) U / L vs. (118.80 ± 28.60) U / L, (101.36 ± 27.32) U / L (123.08 ± 30.59) U / L] (P <0.05). The overall incidence of adverse reactions was significantly lower than that of the control group [20.00% (7/35) vs 42.85% (15/35)] (P < 0.05). Conclusion: The clinical efficacy of decitabine in combination with CAG regimen is superior to that of CAG regimen alone in patients with acute myeloid leukemia, which may be related to its significant reduction of serum IFN-γ, HBDH and LDH levels.